PB
PBLS
Parabilis Medicines, Inc.
$25.85
-0.69%
$3.1B
No data for this timeframe.
Vol
Market Cap$3.1B
Cap SizeMid Cap
Insider Activity4B / 0S
Insider Net $$395.2M
SEC Reports14
Press Releases1
Recent Activity
Jun 16, 2026
SEC
RA Capital Management, a director and 10% owner, purchased 19.73M shares of PBLS for $394.57M at $20/share on June 11, r
CLUSTER — Impact 8/10
Jun 15, 2026
SEC
Parabilis Medicines insiders executed a massive $394.8M open-market purchase and converted millions of derivative shares
CLUSTER — Impact 9/10
Jun 15, 2026
Insider
SEBULSKY ALAN bought 5,000 shares
Director @ $26.00 ($130.0K)
Jun 15, 2026
short_volume
Short Volume: PBLS — 60.5% short (0.4M / 0.6M)
Short: 354,236 | Exempt: 400 | TRF Vol: 585,652 | Short Ratio: 60.5% | Off-exchange volume (dark poo
Jun 12, 2026
Insider
SEBULSKY ALAN bought 8,435 shares
Director @ $27.67 ($233.4K)
Jun 11, 2026
SEC
Parabilis Medicines completed its IPO and simultaneously closed a $75M private placement with Regeneron at a 10% discoun
8-K — Impact 6/10
Jun 11, 2026
Insider
Flynn James E acquired 122,990 shares
10%+ Owner
Jun 10, 2026
Press
Parabilis Medicines priced its upsized IPO of 33.5M shares at $20.00/share, expecting gross proceeds of $670M, plus a co
Impact 7/10
Latest Reports
BULLISH
CLUSTER
8/10
RA Capital Management, a director and 10% owner, purchased 19.73M shares of PBLS for $394.57M at $20/share on June 11, r
Jun 16, 2026
BULLISH
CLUSTER
9/10
Parabilis Medicines insiders executed a massive $394.8M open-market purchase and converted millions of derivative shares
Jun 15, 2026
BULLISH
Press
7/10
Parabilis Medicines priced its upsized IPO of 33.5M shares at $20.00/share, expecting gross proceeds of $670M, plus a co
Jun 10, 2026
Recent Insider Trades
| Date | Insider | Type | Value |
|---|---|---|---|
| Jun 15, 2026 | SEBULSKY ALAN | BUY | $130.0K |
| Jun 12, 2026 | SEBULSKY ALAN | BUY | $233.4K |
| Jun 11, 2026 | Flynn James | C | $0.00 |
| Jun 11, 2026 | Flynn James | C | $0.00 |
| Jun 11, 2026 | Flynn James | C | $0.00 |
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
9 unique insiders with 26 transactions. Net insider value: $395.2M ($395.2M bought, $0.00 sold).
Insider Transactions
| Date | Insider | Title | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Jun 15, 2026 | SEBULSKY ALAN | Director | BUY | 5,000 | $26.00 | $130.0K |
| Jun 12, 2026 | SEBULSKY ALAN | Director | BUY | 8,435 | $27.67 | $233.4K |
| Jun 11, 2026 | Flynn James E | 10%+ Owner | CONVERT | 122,990 | — | — |
| Jun 11, 2026 | Flynn James E | 10%+ Owner | CONVERT | 166,070 | — | — |
| Jun 11, 2026 | Flynn James E | 10%+ Owner | CONVERT | 143,650 | — | — |
| Jun 11, 2026 | Flynn James E | 10%+ Owner | CONVERT | 246,732 | — | — |
| Jun 11, 2026 | Flynn James E | 10%+ Owner | CONVERT | 464,550 | — | — |
| Jun 11, 2026 | SEBULSKY ALAN | Director | BUY | 12,500 | $20.00 | $250.0K |
| Jun 11, 2026 | FITZGERALD EDWARD M | Director | CONVERT | 5,539 | — | — |
| Jun 11, 2026 | FITZGERALD EDWARD M | Director | CONVERT | 8,111 | — | — |
| Jun 11, 2026 | FITZGERALD EDWARD M | Director | CONVERT | 5,332 | — | — |
| Jun 11, 2026 | FITZGERALD EDWARD M | Director | CONVERT | 3,666 | — | — |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | CONVERT | 6,556,740 | — | — |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | BUY | 19,728,353 | $20.00 | $394.6M |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | CONVERT | 642,250 | — | — |
| Jun 11, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | CONVERT | 9,445,363 | — | — |
| Jun 11, 2026 | Borisy Alexis | Director | CONVERT | 105,414 | — | — |
| Jun 11, 2026 | Borisy Alexis | Director | CONVERT | 162,221 | — | — |
| Jun 9, 2026 | SEBULSKY ALAN | Director | AWARD | 39,792 | — | — |
| Jun 9, 2026 | Klausner Richard | Director | AWARD | 20,215 | — | — |
| Jun 9, 2026 | FITZGERALD EDWARD M | Director | AWARD | 20,215 | — | — |
| Jun 9, 2026 | Simson Jake | Director | AWARD | 20,215 | — | — |
| Jun 9, 2026 | Yeshwant Krishna | Director | AWARD | 20,215 | — | — |
| Jun 9, 2026 | Borisy Alexis | Director | AWARD | 20,215 | — | — |
| Jun 9, 2026 | Weber Barbara | Director | AWARD | 20,215 | — | — |
| Jun 9, 2026 | RA CAPITAL MANAGEMENT, L.P. | Director | AWARD | 20,215 | — | — |
14 SEC filing reports analyzed. Sentiment: 7 bullish, 0 bearish, 1 mixed, 6 neutral. Avg impact: 4.9/10.
BULLISH
CLUSTER
8/10
RA Capital Management, a director and 10% owner, purchased 19.73M shares of PBLS for $394.57M at $20
Jun 16, 2026
BULLISH
CLUSTER
9/10
Parabilis Medicines insiders executed a massive $394.8M open-market purchase and converted millions
Jun 15, 2026
MIXED
8-K
6/10
Parabilis Medicines completed its IPO and simultaneously closed a $75M private placement with Regene
Jun 11, 2026
BULLISH
424B4
7/10
Parabilis Medicines priced its IPO of 33,500,000 shares at $20.00/share, raising approximately $623.
Jun 10, 2026
BULLISH
EFFECT
7/10
Parabilis Medicines' S-1 registration statement (File No. 333-296032) became effective on June 9, 20
Jun 10, 2026
NEUTRAL
3
2/10
Mathai Mammen, President & CEO of Parabilis Medicines, filed a Form 3 initial statement of beneficia
Jun 10, 2026
NEUTRAL
3
1/10
Alan Sebulsky filed a Form 3 initial statement of beneficial ownership with Parabilis Medicines, Inc
Jun 10, 2026
NEUTRAL
3
1/10
Krishna Yeshwant filed a Form 3 initial statement of beneficial ownership with Parabilis Medicines,
Jun 10, 2026
NEUTRAL
3
2/10
Richard Klausner filed a Form 3 initial statement of beneficial ownership with Parabilis Medicines,
Jun 10, 2026
NEUTRAL
3
2/10
Edward M. Fitzgerald filed a Form 3 initial statement of beneficial ownership with the SEC, disclosi
Jun 10, 2026
NEUTRAL
3
2/10
Alexis Borisy filed a Form 3 initial statement of beneficial ownership with Parabilis Medicines, Inc
Jun 10, 2026
BULLISH
S-1/A
7/10
Parabilis Medicines, a clinical-stage biopharmaceutical company developing Helicon therapeutics for
Jun 9, 2026
BULLISH
S-1/A
7/10
Parabilis Medicines, a clinical-stage biopharmaceutical company developing Helicon therapeutics for
Jun 4, 2026
BULLISH
S-1/A
7/10
Parabilis Medicines is a pre-IPO biotech filing an amended S-1 registration statement, disclosing a
May 27, 2026
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next Q | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Current FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
| Next FY | $0.00 | $0.00 | $0.00 | — | — | — | $0.0B | — | — |
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.
Jun 15, 2026
short_volume
Short Volume: PBLS — 60.5% short (0.4M / 0.6M)
Short: 354,236 | Exempt: 400 | TRF Vol: 585,652 | Short Ratio: 60.5% | Off-exchange volume (dark pool + OTC)
Jun 11, 2026
offering
Parabilis Medicines Announces Closing of Upsized Initial Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
<p align="left">CAMBRIDGE, Mass., June 11, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biophar
Jun 10, 2026
fda
Parabilis Medicines Announces Pricing of Upsized Initial Public Offering
<p align="left">CAMBRIDGE, Mass., June 09, 2026 (GLOBE NEWSWIRE) -- Parabilis Medicines, Inc. (Nasdaq: PBLS) (“Parabilis”), a clinical-stage biophar